Soleno Therapeutics jumped on Thursday after the drugmaker won US approval for its drug to treat insatiable hunger caused by a genetic disorder.

Shares of the Redwood City, California-based company climbed 38% — the biggest one-day gain since September 2023 — to their highest level in more than eight years.

Related Articles